AzTrials
AzTrials

Vascular Access Device ComplicationsNCT06547294

Does a Novel Needle Over Catheter Device Improve First Pass Success and Decrease Complications

A study testing Osprey IV in people with Vascular Access Device Complications and Catheterization, Peripheral, run by Community Medical Center, Toms River, NJ at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Osprey IV
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
Feb 2025to Sep 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • Any gender, < 18 years old.
  • Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);
  • Previous venous grafts or surgery at the target vessel access site;
  • Currently involved in other investigational clinical trials (unless permission is granted by other study Pl)
  • Subjects who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Robert Wood Johnson Barnabas Health Community Medical Center

    Toms River, New Jersey, 08755

Other trials in United States

About this study

Official title: Procedural and Post-Procedural Clinical Performance of a Novel Peripheral Intravenous Needle Over Catheter Device (OspreyTM)

Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. A standardized data entry sheet will be collected at time of enrollment, and then daily thereafter while the subject has the IV. The data collected will remain anonymous.

Read the detailed description

Identification of Subjects:

The emergency department is a designated participating unit providing subjects with medical care that are anticipated to be placed in the observation unit or admitted to an inpatient unit. Subjects who meet inclusion criteria will be consented to be included in the study.

Assignment of Subject Identification Number:

A unique identification number will be given to study subjects. Subject numbers will be assigned in sequential order. The subject number will consist of 6 characters. The first three characters will designate the manufacturer-specific protocol number (SVI). The last three characters will designate the subject by number in sequential order.

Informed Consent:

The nurse trained in placing this device will first consent the patient with written forms provided. All protocol nurses trained in this device will also have completed CITI training courses per our institutional guidelines.

Treatment Assignment:

Within this single arm study, subjects will be assigned to the study in a single treatment group. All patients in the convenience sample who would have received a standard stocked intravenous catheter will instead receive an Osprey catheter provided by the manufacturer. They will be compared against historical controls. Historical controls will be collected from a review of relevant literature, which has been determined to be stable across time and region.

Data Collection Method A Case Report Form (CRF) will be utilized to collect insertion related study data. The CRF will not include any patient identifying information such as name or medical identification number. The subject's demographic (age, race, and gender); baseline information (comorbidities); type of medications/fluids delivered will be documented from already captured Epic documentation.

A second Case Report Form (CRF) will be utilized to collect device performance study data. The CRF will not include any patient identifying information such as name or medical identification number. Device condition (ability to flush and obtain a blood return), Site condition (presence of redness, edema, drainage), patient response (level of pain) and dwell time will be extracted from Epic as this is the current standard practice to do so.

Active patients in the study will be maintained in a file on a secure drive that study personnel have to refer to to follow up active patients. Once active patients are no longer being followed daily, their name will be removed from that file. CRF forms will be filled out by hand and secured in a locked box. The data from both CRFs will be transcribed into a digital worksheet i.e. Microsoft Excel, which will be stored on a secured network drive maintained by the hospital.

Study Procedure Subjects will be admitted into the study according to the aforementioned criteria.

Hospital protocols will be followed for placement of the PIV. The site will be marked with date, time and initials of inserter. During and immediately after the IV placement procedure, the CRF will be initiated by staff associated with this study. If unsuccessful with first attempt at PIV placement, an attempt at another site with the same technique and device will be performed. This will be repeated according to facility policy and procedure until a successful PIV is in place or the physician decides to use an alternative therapy that no longer requires peripheral access. All catheters will be stabilized using the same form of stabilization device for uniformity in securement procedure throughout the duration of the study.

Daily assessments will occur per facility policy and procedure. An assessment will include; any level of pain and/or tenderness; presence of erythema; edema; induration; leakage of fluid or purulent drainage from the puncture site; catheter dysfunction (eg, resistance when flushing, absence of a blood return. Daily assessment will continue until the device is removed, completion of therapy or discharge. Once all the required data is collected, all de-identified data will be entered as a "data set" into the post procedure CRF for management/analysis. The final paper CRF will be placed in a study folder and maintained for record keeping and data analysis.

Being tested
Osprey IV, Historical Controls

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Osprey IVDevice

    Utilization of novel needle over catheter commercial insertion device

  • Historical ControlsOther

    Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)

Study groups in NCT06547294
Study groupRoleWhat they receive
Osprey IVExperimentalSubjects enrolled will receive the study device as part of their routine medical care.
Receives: Device: Osprey IV; Other: Historical Controls

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Attempts

    The number of attempts that operator needs to access vein and secure device for proper bidirectional flow

    Measured: 10 minutes

Secondary outcomes (9)
  1. Blood culture contamination rates

    Proportion of blood culture specimens (when drawn) that are reported with contaminants

    Measured: 1 week

  2. Flushing characteristic

    whether operator finds flow into patient to be impeded or unimpeded

    Measured: 10 minutes

  3. Patient discomfort

    Patient's self assessment of level of pain experienced by insertion

    Measured: 10 minutes

  4. Time to removal

    Total days device remained in place

    Measured: 1 week

  5. Removal reason

    If removed for device failure vs cessation of therapy

    Measured: 1 week

  6. Edema

    Presence of edema

    Measured: 1 week

  7. Redness

    Presence of redness

    Measured: 1 week

  8. Drainage

    Presence of drainage

    Measured: 1 week

  9. Site Pain

    Presence of site pain

    Measured: 1 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Aug 2024
  2. Study startFeb 2025 (estimated)
  3. Primary completionApr 2025 (estimated)
  4. Study completionSep 2025 (estimated)

Why it stopped: Device manufacturer withdrew support

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single arm with historical controls
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06547294
Sponsor's protocol ID
Pro2024001057
Status last verified
Oct 2026
First submitted
7 Aug 2024
Last updated
22 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Osprey IV in people with Vascular Access Device Complications and Catheterization, Peripheral, run by Community Medical Center, Toms River, NJ at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Attempts (time frame: 10 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in